Loading clinical trials...
Loading clinical trials...
A Phase III, Double-blind, Placebo-controlled, Randomized Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Conditions
Interventions
Atezolizumab
Ipatasertib
+3 more
Locations
182
United States
USA Mitchell Cancer Institute
Mobile, Alabama, United States
Highlands Oncology Group
Springdale, Arkansas, United States
UCLA
Los Angeles, California, United States
Kaiser Permanente-SCPMG; Oncology Research
San Diego, California, United States
Stanford Cancer Center
Stanford, California, United States
Kaiser Permanente - Franklin
Denver, Colorado, United States
Start Date
November 25, 2019
Primary Completion Date
February 28, 2023
Completion Date
February 28, 2023
Last Updated
March 27, 2024
NCT06393374
NCT06257264
NCT05491226
NCT07525869
NCT05660083
NCT05768932
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions